Supplemental Figure S1 and Figure S2 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer

Fig S1. BMS566394 inhibits EGFR signaling in CXCL12 treated HCT116 cells; Fig S2. Schema for CXCL12-CXCR4 transactivation of colon cancer cell EGFR. Shown in the figure are inhibitors or antibodies used in this study: AMD3100 blocks CXCR4; BMS566394 blocks ADAM17 and INCB3619 blocks ADAM17 and ADAM10; C225 antibodies block ligand binding to EGFR.